CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-04-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/52 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839573425620779008 |
|---|---|
| author | P. A. Isaev P. O. Rumyantsev V. V. Polkin A. A. Ilyin D. Yu. Syomin T. A. Agababyan S. V. Vasilkov V. S. Medvedev |
| author_facet | P. A. Isaev P. O. Rumyantsev V. V. Polkin A. A. Ilyin D. Yu. Syomin T. A. Agababyan S. V. Vasilkov V. S. Medvedev |
| author_sort | P. A. Isaev |
| collection | DOAJ |
| description | The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization. |
| format | Article |
| id | doaj-art-a3b54c5c44cc4a929dc1b83bea2764f9 |
| institution | Matheson Library |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2015-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-a3b54c5c44cc4a929dc1b83bea2764f92025-08-04T14:05:30ZrusABV-pressОпухоли головы и шеи2222-14682411-46342015-04-0102465010.17650/2222-1468-2014-0-2-46-5052CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131IP. A. Isaev0P. O. Rumyantsev1V. V. Polkin2A. A. Ilyin3D. Yu. Syomin4T. A. Agababyan5S. V. Vasilkov6V. S. Medvedev7Medical Radiology Research Center, Ministry of Health of Russia, ObninskEndocrinology Research Center, Ministry of Health of Russia, MoscowMedical Radiology Research Center, Ministry of Health of Russia, ObninskMedical Radiology Research Center, Ministry of Health of Russia, ObninskMedical Radiology Research Center, Ministry of Health of Russia, ObninskMedical Radiology Research Center, Ministry of Health of Russia, ObninskMedical Radiology Research Center, Ministry of Health of Russia, ObninskMedical Radiology Research Center, Ministry of Health of Russia, ObninskThe treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.https://ogsh.abvpress.ru/jour/article/view/52the differentiated thyroid cancer resistant to therapy 131idecisionmulti-kinase inhibitornexavar (sorafenib) |
| spellingShingle | P. A. Isaev P. O. Rumyantsev V. V. Polkin A. A. Ilyin D. Yu. Syomin T. A. Agababyan S. V. Vasilkov V. S. Medvedev CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I Опухоли головы и шеи the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) |
| title | CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I |
| title_full | CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I |
| title_fullStr | CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I |
| title_full_unstemmed | CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I |
| title_short | CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I |
| title_sort | clinical experience of nexavar sorafenib application in patients with metastatic differentiated thyroid cancer resistant to therapy 131i |
| topic | the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib) |
| url | https://ogsh.abvpress.ru/jour/article/view/52 |
| work_keys_str_mv | AT paisaev clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i AT porumyantsev clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i AT vvpolkin clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i AT aailyin clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i AT dyusyomin clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i AT taagababyan clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i AT svvasilkov clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i AT vsmedvedev clinicalexperienceofnexavarsorafenibapplicationinpatientswithmetastaticdifferentiatedthyroidcancerresistanttotherapy131i |